Affy Posts 6 Percent Decrease in Q2 Sales as it Prepares to Launch Next-Gen Genotyping Offering

According to CEO Kevin King, Affy's "efforts to prepare the company for renewed revenue growth and profitability … have started to pay off."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.